- Home
- ETNB vs DNTH Comparison
ETNB vs DNTH Comparison
Compare ETNB & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETNB
- DNTH
- Stock Information
- Founded
- ETNB 2018
- DNTH 2015
- Country
- ETNB United States
- DNTH United States
- Employees
- ETNB N/A
- DNTH N/A
- Industry
- ETNB Biotechnology: Pharmaceutical Preparations
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- ETNB Health Care
- DNTH Health Care
- Exchange
- ETNB Nasdaq
- DNTH Nasdaq
- Market Cap
- ETNB 867.4M
- DNTH 711.2M
- IPO Year
- ETNB 2019
- DNTH N/A
- Fundamental
- Price
- ETNB $8.04
- DNTH $24.27
- Analyst Decision
- ETNB Buy
- DNTH Strong Buy
- Analyst Count
- ETNB 7
- DNTH 8
- Target Price
- ETNB $30.33
- DNTH $46.43
- AVG Volume (30 Days)
- ETNB 800.5K
- DNTH 192.9K
- Earning Date
- ETNB 11-07-2024
- DNTH 11-07-2024
- Dividend Yield
- ETNB N/A
- DNTH N/A
- EPS Growth
- ETNB N/A
- DNTH N/A
- EPS
- ETNB N/A
- DNTH N/A
- Revenue
- ETNB N/A
- DNTH $5,366,000.00
- Revenue This Year
- ETNB N/A
- DNTH $98.73
- Revenue Next Year
- ETNB N/A
- DNTH N/A
- P/E Ratio
- ETNB N/A
- DNTH N/A
- Revenue Growth
- ETNB N/A
- DNTH 51.41
- 52 Week Low
- ETNB $7.00
- DNTH $6.58
- 52 Week High
- ETNB $16.63
- DNTH $33.77
- Technical
- Relative Strength Index (RSI)
- ETNB 44.02
- DNTH 47.82
- Support Level
- ETNB $7.44
- DNTH $23.55
- Resistance Level
- ETNB $8.09
- DNTH $24.65
- Average True Range (ATR)
- ETNB 0.44
- DNTH 1.45
- MACD
- ETNB -0.06
- DNTH 0.14
- Stochastic Oscillator
- ETNB 22.47
- DNTH 38.79
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.